(C) PLOS One
This story was originally published by PLOS One and is unaltered.
 . . . . . . . . . .



Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2 [1]

['Wakana Saso', 'Department Of Virology Ii', 'National Institute Of Infectious Diseases', 'Tokyo', 'The Institute Of Medical Science', 'The University Of Tokyo', 'Aids Research Center', 'Masako Yamasaki', 'Department Of Applied Biological Sciences', 'Tokyo University Of Science']

Date: 2022-08 

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been transmitted across all over the world, in contrast to the limited epidemic of genetically- and virologically-related SARS-CoV. However, the molecular basis explaining the difference in the virological characteristics among SARS-CoV-2 and SARS-CoV has been poorly defined. Here we identified that host sialoglycans play a significant role in the efficient spread of SARS-CoV-2 infection, while this was not the case with SARS-CoV. SARS-CoV-2 infection was significantly inhibited by α2-6-linked sialic acid-containing compounds, but not by α2–3 analog, in VeroE6/TMPRSS2 cells. The α2-6-linked compound bound to SARS-CoV-2 spike S1 subunit to competitively inhibit SARS-CoV-2 attachment to cells. Enzymatic removal of cell surface sialic acids impaired the interaction between SARS-CoV-2 spike and angiotensin-converting enzyme 2 (ACE2), and suppressed the efficient spread of SARS-CoV-2 infection over time, in contrast to its least effect on SARS-CoV spread. Our study provides a novel molecular basis of SARS-CoV-2 infection which illustrates the distinctive characteristics from SARS-CoV.

Author summary SARS-CoV-2, which has been highly transmissible and rapidly spreading worldwide, has caused approximately 458 million confirmed cases of COVID-19 with more than 6 million deaths by March 2022. Here we found that SARS-CoV-2 infection was significantly inhibited by α2-6-linked sialic acid-containing compounds and by depletion of cell surface sialic acid with only a minor effect on SARS-CoV infection. We identified that SARS-CoV-2 spike S1 subunit directly binds to α2-6-linked sialoglycans for efficient attachment to host cell surface. Our finding indicated that host sialoglycans play a significant role in the efficient infection of SARS-CoV-2, which provides a novel understanding of the molecular basis explaining the rapid spread of SARS-CoV-2 over SARS-CoV.

Citation: Saso W, Yamasaki M, Nakakita S-i, Fukushi S, Tsuchimoto K, Watanabe N, et al. (2022) Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. PLoS Pathog 18(6): e1010590. https://doi.org/10.1371/journal.ppat.1010590 Editor: Yoshihiro Kawaoka, University of Wisconsin-Madison, UNITED STATES Received: October 31, 2021; Accepted: May 13, 2022; Published: June 14, 2022 Copyright: © 2022 Saso et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: All relevant data are within the manuscript and its Supporting Information files. Funding: This work was supported by the Agency for Medical Research and Development (AMED) (JP20fk0108411 to KW; JP20fk0108511 to KW; JP20fk0108505 to KW; JP20fk0108540 to KW; JP20fk0310114 to KW; JP20jm0210068 to KW; JP20fk0310101 to KW; JP20fk0310103 to KW; JP20wm0325007 to KW; JP22fk0310504 to KW), Japan Society for the Promotion of Science (JP20H03499 to KW; JP21H02449 to KW), JST MIRAI Program to KW, Takeda Science Foundation to KW, Smoking Research Foundation to KW, Taiju Life Social Welfare Foundation to KW, and Kieikai Research Foundation to KW. The funders had no design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist.

Introduction The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of coronavirus disease 2019 (COVID-19), is a public health problem, with an estimated 458 million cases and more than 6 million deaths worldwide by March 2022 [1]. The symptom can range from very mild to severe, including fever, cough, headache, dyspnea, and pneumonia. SARS-CoV-2 is genetically related to SARS-CoV that emerged in 2002. SARS-CoV was highly pathogenic; however, it faded out after having taken intense control measures with a total of about 8,000 infections and 800 deaths [2]. In contrast, SARS-CoV-2 rapidly caused a pandemic with an incredibly high number of worldwide infections, and is still causing social as well as economic damage globally. We previously reported that SARS-CoV-2 achieves its viral load peak in as early as 2.0 days after the onset of its symptoms while that of SARS-CoV peaks at 7.2 days in patients [3]. These evidences highlight the characteristic differences between SARS-CoV-2 and SARS-CoV, which may explain the rapid spread of SARS-CoV-2. The molecular basis underlying the distinct SARS-CoV-2 infection over its related SARS-CoV is not fully understood. It is reported that SARS-CoV-2 receptor binding domain has higher angiotensin-converting enzyme 2 (ACE2) binding affinity than that of SARS-CoV [4,5], which may contribute to the efficient infection of SARS-CoV-2. Other possible explanation for the fast spread of SARS-CoV-2 is that SARS-CoV-2 spike contains furin cleavage site while SARS-CoV does not, thus, allowing SARS-CoV-2 spike to have more chance to be activated for cell entry [5–7]. In this study, we found a novel molecular basis exhibiting the significant role of the host sialic acid in SARS-CoV-2 infection and spread. The cell entry is the first and essential step in the viral life cycle. The coronavirus mostly enters by the binding between host receptors and the viral spike, which undergoes proteolytic cleavage carried out by host proteases. The activation of spike subsequently promotes viral fusion at the cellular or endosomal membrane, thereby allowing the insertion of the viral genome into the cellular cytoplasm. Human-infecting coronaviruses use different host factors for cell entry. Human coronavirus 229E (HCoV-229E) uses aminopeptidase N as a receptor for viral entry into the host cells [8]. Middle East respiratory syndrome coronavirus (MERS-CoV) uses dipeptidyl peptidase 4 (DPP4) [9]. HCoV-NL63, SARS-CoV, and SARS-CoV-2 recognize the same receptor ACE2 [10–14]. There are several coronaviruses that use sialic acids for cell entry [15]. Of these, three viruses are human-infecting coronaviruses: HCoV-OC43 and HCoV-HKU1 use 9-O-acetylated sialic acids as entry receptors [16,17]; whereas MERS-CoV, in addition to DPP4, utilize sialylated glycans during the early attachment phase [18]. While SARS-CoV infection is likely to be independent or minimally dependent on host sialic acid for its attachment [18,19], the role of sialic acid in SARS-CoV-2 infection has been suggested by in silico predictions and in vitro analysis [20–23]. Only a recent report performed experimental infection studies using viral particles and revealed that sialylated glycans facilitate SARS-CoV-2 infection [24]. These findings highlight the need for further investigation on sialic acid’s role in SARS-CoV-2 infection. In this study, we screened a series of compounds using SARS-CoV-2 cell culture-based assay and identified α2-6-linked sialic acid-containing compounds to inhibit viral infection. SARS-CoV-2 infection was inhibited by α2-6SLN-lipo-PGA compound in VeroE6/TMPRSS2 and Calu-3 cells. α2-6-linked sialylated glycans targeted SARS-CoV-2 spike S1 subunit to inhibit viral attachment to the host cells. Furthermore, enzymatic removal of endogenous sialic acids on the cell surface by neuraminidase suppressed the spread of SARS-CoV-2 infection, but this was not the case with SARS-CoV. Our study revealed that SARS-CoV-2 utilizes cell surface sialic acid which can support the virus binding to its receptor ACE2. The finding provides novel insight into the molecular basis for the unique characteristics of SARS-CoV-2 infection and spread.

Discussion In this study, using cell culture-based infection assay, we identified that α2-6-linked sialic acid-containing compounds inhibited SARS-CoV-2 infection, but not SARS-CoV. It was revealed that the compound targeted virus particles to inhibit viral attachment to cells. In vitro analysis using recombinant SARS-CoV-2 spike protein and sialylglycopeptides consistently showed that α2-6-linked sialylated glycan directly interacted with the S1 subunit of SARS-CoV-2 spike protein. We demonstrated that depletion of sialic acids from the cell surface using neuraminidase impaired the interaction between SARS-CoV-2 spike and ACE2, and eventually suppressed the spread of SARS-CoV-2 infection, while SARS-CoV spread was independent of the removal of sialic acid. Our data clearly indicated the distinct difference in the infection dependency on sialic acids between SARS-CoV-2 and SARS-CoV. These findings suggest that host sialosides play an important role in the efficient infection of SARS-CoV-2. The sialic acid-binding capacity is one of the many determinants of biological diversity in the family of coronavirus. Several coronaviruses have been reported to interact with sialic acids, including HCoV-OC43, HCoV-HKU1, bovine CoV (BCoV), mouse hepatitis virus, MERS-CoV, transmissible gastroenteritis virus, and infectious bronchitis virus [16–18,29,30]. For HCoV-OC43 and HCoV-HKU1, 9-O-acetylated-Sia (Neu5,9Ac 2 ) is the sole receptor, in which the binding critically determines the cell entry of the virus. In contrast, the sialic acid use of SARS-CoV-2 is more similar to that of MERS-CoV, which involves binding to the cell surface of sialylated glycans contributing to the efficiency of binding to their entry receptor DPP4. Fantini et al. [31] proposed a dual receptor/attachment model for SARS-CoV-2 with the spike protein involved in ACE2 receptor recognition and finding sialylated sphingoglycolipid (ganglioside)-rich landing area (lipid rafts) at the cell surface. Considering our result that depletion of cell surface sialic acids reduces the capacity of cells for the binding of SARS-CoV-2 particles with the impairment of ACE2 interaction to the viral spike protein, the interaction of SARS-CoV-2 with sialic acids may be responsible for the early contact with host cells, which can serve in concentrating the viruses on the surface of target cells, facilitating their binding to high-affinity receptor ACE2. The genome sequence homology of SARS-CoV-2 exhibits 79.6% similarity with SARS-CoV, and they share the same receptor ACE2 for their entry into host cells [12–14]. Despite the similarities, our data demonstrated one of their differences that SARS-CoV-2 has the ability to use host cell sialosides while SARS-CoV does not. The N-terminal domain (NTD) of spike protein is responsible for glycan binding in other coronaviruses such as BCoV, HCoV-OC43, and MERS-CoV. The NTD sequence of SARS-CoV-2 and SARS-CoV show only 53.5% of homology, while full-length spike proteins share almost 76% identities [19]. Seyran et al. [20] proposed the presence of the distinct flat and non-sunken sialic acid-binding domain in SARS-CoV-2 S1-NTD which enables faster viral surfing over the epithelium. This promotes faster viral movement to ACE2 receptor compared to other human coronaviruses such as SARS-CoV. Moreover, the structure-based sequence comparison of the spike protein of SARS-CoV, SARS-CoV-2, and MERS-CoV identified that SARS-CoV-2 S1-NTD contains structural regions reminiscent of MERS-CoV sialoside binding pockets [21,22]. The sialic acid binding of recombinant SARS-CoV-2 spike was experimentally investigated by Baker et al. [23] using gold nanoparticles bearing sialic acid, which demonstrated that αNeu5Ac is a ligand for spike glycoprotein, although they did not examine the function of αNeu5Ac in virus infection. Nguyen et al. [24] presented a new idea that receptor binding domain (RBD) of SARS-CoV-2 spike is involved in the recognition of sialylated glycans. They performed in vitro glycan library screening against SARS-CoV-2 RBD and S protein, which revealed that several sialic acid-containing structures are recognized. The usage of glycolipids by SARS-CoV-2 was confirmed by pharmacological abrogation in viral infection. These findings are consistent with our result that SARS-CoV-2 S1 interact with sialic acid-containing molecules, which supports viral entry into host cells. Sialic acids are widely distributed in human tissues and sialylated glycans are present in glycoproteins (N-glycans, O-glycans), glycosphingolipids (gangliosides), certain GPI anchors, polysialic acids, and others [32,33]. Most sialic acid-binding viruses appear to bind to non-reducing terminal sialic acid linked to a penultimate sugar residue galactose (Gal) via an α2–6 or α2–3 linkage [34–37]. HCoV-OC43 prefers Neu5,9Ac 2 linked to Gal via α2–6 over α2–3 linkage [38]. MERS-CoV binds to sialylated glycans containing α2-3-linked sialic acids rather than α2–6, which correlates with the differential distribution of α2–3 or α2-6-linked sialic acids in the target cells of the hosts [18,39]. Our study demonstrated that SARS-CoV-2 infection was effectively inhibited by α2-6SLN-lipo-PGA and α2-6SLN-PGA, and SARS-CoV-2 spike protein was preferentially bound to α2-6Neu5Ac-containing SGP. The sialylated glycans that were used in this study possessed α2-6-linked sialyllactosamine type 2 sequence [αNeu5Ac-(2–6)-βGal-(1–4)-βGlcNAc-1-]. Glycans possessing sialyllactosamine type 2 sequences are ubiquitously distributed in human respiratory tract with different sialic acid linkages and lactosamine repeats [40–44]. α2–6 sialylated glycans are predominantly expressed in a human’s upper respiratory tissues, while the lower respiratory tract including lung and bronchi contains a mixture of α2–3 and α2–6 linkage. Interestingly, ACE2 expression in the respiratory tissue is limited as compare to other organs such as the heart or kidney [45,46]. Above results may indicate that glycans consisting of α2-6-linked sialyllactosamine type 2 sugar chains at upper and lower respiratory tissues mediate efficient SARS-CoV-2 spread in the limited ACE2-expressing cells. This may consequently result in the short interval until the viral load peaks in patients. Also, SARS-CoV-2 interactions with sialylated glycans at upper respiratory tract may contribute to the efficient transmission to other organisms by respiratory fluids, which possibly caused the rapid spread of SARS-CoV-2 throughout the world as compared to the SARS-CoV. However, precise preference of SARS-CoV-2 for various types of sialoside requires further analysis in future studies. As the viral entry process is essential for initiation, spread, and maintenance of infection, this step is an attractive target for the development of antiviral agents. Our finding, that SARS-CoV-2 utilizes sialic acids for its entry, provides novel insight into understanding the molecular mechanisms of SARS-CoV-2 infection and the role of sialylated glycans in viral entry as well as the developing antiviral strategies.

Materials and methods Cell culture VeroE6 cells overexpressing transmembrane protease, serine 2 (TMPRSS2) [47,48] were cultured in Dulbecco’s modified Eagle’s medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS; Cell Culture Bioscience), 100 units/mL penicillin, 100 μg/mL streptomycin, 10 mM HEPES (pH 7.4), and 1 mg/mL G418 (Nacalai) at 37°C in 5% CO 2 . During the infection assay, 10% FBS was replaced with 2% FBS and G418 removed. Calu-3 cells were cultured in the above medium without G418. Reagents Remdesivir was purchased from Chemscene, lopinavir from Selleck, chloroquine from Nacalai Tesque, heparin from Mochida Pharmaceutical, neuraminidase from Roche and Nacalai Tesque, anti-ACE2 antibody from R&D Systems, glycopeptides (α2-6-SGP, α2-3-SGP, and asialo-SGP) from Fushimi Pharmaceutical, 2-O-methyl α-D-N-acetylneuraminic acid (Me-α-Neu5Ac) and α2–6 sialyllactose sodium salt from Nagara Science, and recombinant SARS-CoV-2 spike S1 and ACE2 proteins from Sino Biological. Compound synthesis αNeu5Ac-(2–3)-βGal-(1–4)-βGlcNAc-1-aminopentyl-poly-γ-L-glutamic acid (α2-3SLN-PGA) and αNeu5Ac-(2–6)-βGal-(1–4)-βGlcNAc-1-aminopentyl-poly-γ-L-glutamic acid (α2-6SLN-PGA) used in this study were synthesized as described previously [49]. αNeu5Ac-(2–6)-βGal-(1–4)-GlcNAc-lipo-poly-α-L-glutamic acid (α2-6SLN-lipo-PGA) was prepared in-house according to a procedure previously reported [25]. The concept of the polymer design is important where negatively charged poly-Glu backbone with or without hydrophilic glycans has random coil structure, however, introduction of lipophilic tail prompts its form more globular overall by intra-hydrophobic interactions. This is advantageous for presentation of glycan part to outer layer of the globule. Since the degree of substitution (DS) is low, such hydrophobic interaction is rather unstable. Thus, on binding with a viral protein, the polymer structure become unstable, and the exposed lipid tails interact with nearby hydrophobic environment possibly insertion into a hydrophobic patch of a protein or into lipid bilayer. The lipid chain connected to Lys in α2-6SLN-lipo-PGA has been shown to mimic sphingosine. The content of sialic acid moiety (approximately 5 mol%) was estimated according to the 1H-nuclear magnetic resonance analysis (Advance 500 spectrometer, Bruker Biospin). βGal-(1–4)-βGlc-1-sphingosine-poly-α-L-glutamic acid (LS-PGA) was prepared in-house according to a procedure similar to one reported [50]. Briefly, a solution of LS (0.13 mg, 0.2 mmol) and PGA sodium salt (average mol. wt. 84,600, 3.0 mg, 10 equiv. as L-Glu) dissolved in 15 mL of THF-H 2 O (2:1) was added 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM, 6.0 mg, 20 mmol), and the resulting mixture was stirred overnight at 40°C. After the disappearance of starting amine was confirmed by TLC (EtOAc/MeOH/H 2 O = 2:1:1), the reaction mixture was concentrated to give a residue, which was then dissolved in 5% NaHCO 3 , loaded onto a G-25 column, and eluted with MeOH to afford LS-PGA. The degree of substitution of LS in the polymer was about 10 mol%. SARS-CoV-2 and SARS-CoV infection assay VeroE6/TMPRSS2 cells were seeded in 96 well plates a day before virus infection. The cells were inoculated with SARS-CoV-2 Wk-521 strain, a clinical strain isolated from a COVID-19 patient [47], or SARS-CoV Frankfurt strain at a multiplicity of infection (MOI) of 0.001 or 0.003 for 1 h and the unbound virus was removed by washing. Cells were cultured for 24 h prior to measuring the extracellular viral RNA or detecting viral encoded N protein. Compounds were added during virus inoculation (1 h) and replenished after washing (24 h). Infection assay with Calu-3 cells was performed by incubation with virus at a MOI of 0.1 for 3 h. Extracellular viral RNA was detected at 72 h post-inoculation. For the calculation of MOI, viral titers (50% tissue culture infective dose: TCID 50 ) were determined by Behrens-Karber method [51]. Quantification of viral RNA Viral RNA was extracted with a QIAamp Viral RNA Mini Kit (QIAGEN), RNeasy Mini Kit (QIAGEN) or MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit (Thermo Fisher Scientific) and quantified by real time RT-PCR analysis with a one-step qRT-PCR kit (THUNDERBIRD Probe One-step qRT-PCR kit, TOYOBO) using 5’-ACAGGTACGTTAATAGTTAATAGCGT-3’, 5’- ATATTGCAGCAGTACGCACACA-3’, and 5’-FAM-ACACTAGCCATCCTTACTGCGCTTCG-TAMRA-3’ (SARS-CoV-2 and SARS-CoV relative quantification) [52]; 5’-AAATTTTGGGGAVVAGGAAC-3’, 5’-TGGCAGCTGTGTAGGTCAAC-3’, and 5’-FAM-ATGTCGCGCATTGGCATGGA-TAMRA-3’ (SARS-CoV-2 absolute quantification); 5’-GAACAAACCCAAGGAAATTT-3’, 5’-GGATCTTTGTCATCCAATTT-3’, and 5’-FAM-ATGTCGCGCATTGGCATGGA-TAMRA-3’ (SARS-CoV absolute quantification). Cell viability At 24 h post infection, the same time point when culture supernatant was collected to measure extracellular viral RNA, cells were washed with PBS and fixed with 4% paraformaldehyde. Then the cells were stained with DAPI. Cell viability was determined by the quantification of survived cell numbers by counting the number of detected nucleus with three cell culture wells (one microscopic field in each well) in a 96 well plate using a high content imaging analyzer ImageXpress Micro Confocal (Molecular Device) [53,54]. Indirect immunofluorescence analysis The cells were fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100. To detect viral protein expression, the cells were treated with a rabbit anti-SARS-CoV/SARS-CoV-2 N antibody [55] as a primary antibody, and then incubated with Alexa594-conjugated secondary antibody and DAPI. N-positive cells (Fig 5F-b) were quantified by calculating fluorescent stained area of three cell culture wells (one microscopic field in each well) in a 96 well plate using hybrid cell count system in BZ-X Analyzer (BZ-X710, KEYENCE). Time of addition analysis VeroE6/TMPRSS2 cells were inoculated with virus at an MOI of 0.001 for 1h and the unbound virus was removed by washing. Cells were cultured for 24 h and the amount of viral RNA in the supernatant was measured as an indicator of released virus particles. Compounds were added with three different timing: (a, whole) compounds present throughout the experiment, (b, entry) compounds were treated for 1 h during viral inoculation and an additional 2 h and then removed, and (c, post-entry) compounds were added at 2 h after washing free viruses and remained throughout the experiment [56–58]. Viral RNA in culture supernatant was measured as described above. SARS-CoV-2 and SARS-CoV pseudovirus infection assay SARS-CoV-2 and SARS-CoV pseudoviruses were produced using vesicular stomatitis virus (VSV)-pseudovirus system as described previously [59,60] using expression plasmids encoding SARS-CoV-2 or SARS-CoV spike protein and the G-deficient VSV which carries the luciferase gene instead of the VSV-G gene. This pseudoviruses infect the target cells in a spike-dependent manner and produce luciferase activity in infected cells. VeroE6/TMPRSS2 cells were inoculated with SARS-CoV-2 or SARS-CoV pseudovirus in the presence or absence of compounds and intracellular luciferase activity was measured at 24 h post-inoculation using Luciferase Assay System (Promega). Virus-cell attachment assay VeroE6/TMPRSS2 cells were incubated with viruses in the presence or absence of compounds for 5 min (Fig 3D) or 60 min (Fig 5B) at 4°C. After washing the unbound virus, the attached viral RNA was extracted with RNeasy Mini Kit (QIAGEN) and quantified by real time RT-PCR. Compound treatment to SARS-CoV-2 particles or host cells To evaluate the effect of compounds on SARS-CoV-2 particles, virus was treated with or without compounds for 60 min at 37°C, and unbound compounds were subsequently removed by ultrafiltration using centrifugal filter devices (Pall Corpotation). The viral sample ultrafiltrated without compound was used as a control. The attachment capacity of compound-treated virus was evaluated by treating VeroE6/TMPRSS2 cells in the absence of compounds for 30 min at 4°C, and then extracting the attached viral RNA with RNeasy Mini Kit (QIAGEN) for quantification by real time RT-PCR. To evaluate the effect of compounds on host cells, VeroE6/TMPRSS2 cells were pretreated with compounds for 30 min at 37°C before being washed. The capacity of compound-treated cells to virus attachment was measured by inoculating the cells with virus for 30 min at 4°C in the absence of compounds and detecting the attached viral RNA. The glycan array Glycopeptide conjugated BSA was prepared by glycoconjugation of BSA using N-(3-maleimidobenzoyloxy) succinimide (Nacalai), with each glycopeptide by catalytic reaction. Preparation of the glycopeptide conjugated BSA microarray and binding assay of glycan microarray were carried out as reported previously [61,62]. The amount of glycans on the neoglycoprotein was determined by liberation of glycans, fluorescence labeling and quantified by HPLC (α2-6-SGP and asialo-SGP were 10.8 mol glycan/ 1 mol BSA and α2-3-SGP was 10.5 mol glycan/1 mol of BSA). Anti-SARS-CoV-2 S1 antibody (prepared in house) was used as a primary antibody, and Cy3-conjugated anti-rabbit IgG was used as secondary antibody. Following MIRAGE guidelines, information on the glycan array is shown. Glycand binding sample and assay conditions: Recombinant SARS-CoV-2 spike S1 (Sino Biological) Glycan library: α2-6-SGP, α2-3-SGP, and asialo-SGP (Fushimi Pharmaceutical) were conjugated to BSA by m-maleimidobenzoyl-N-hydroxysuccinimide ester. Printing surface: Epoxy coated slide glass (Rexxam). Array Printer: BioJet plus displacer AD1500 (BioDot) Glycan microarray with "map": The glycan signals of triplicate spots were averaged and normalized to the mean value of 21 glycans immobilized on the array. Detector and data processing: Evanescent Fluorescence Scanner Bio-REX Scan 200 (Rexxam). Glycan microarray data presentation: The results are shown in Fig 4. Interpretation and conclusion from microarray data: α2-6-sialoglycans were bind to recombinant SARS-CoV-2 spike S1. Neuraminidase treatment To examine the role of sialic acid in virus infection, VeroE6/TMPRSS2 cells were incubated with neuraminidase derived from either Vibrio cholerae (Roche) or Arthrobacter ureafaciens (Nacalai) for 2 h at 37°C. After washing cells to remove neuraminidase, SARS-CoV-2 and SARS-CoV pseudovirus infection assay or SARS-CoV-2 attachment assay was performed as described above. Lectin staining For detection of sialic acids, VeroE6/TMPRSS2 cells were fixed with 4% paraformaldehyde. Biotinylated elderberry bark lectin and biotinylated Maackia amurensis lectin II (Vector Labs) were used to stain α2–6 and α2–3 sialic acid, respectively. The lectins were added into fixed cells for 1 h at room temperature, then streptavidin-conjugated Alexa Fluor 594 (Thermo Fisher Scientifics) and DAPI were added for 1 h at room temperature. The fluorescence images were captured using confocal microscopy TCS SP8 (Leica). Co-immunoprecipitation analysis The cells were lysed with the buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% NP-40 and complete protease inhibitor], followed by an immunoprecipitation with anti-ACE2 antibody (R&D Systems) or mouse normal IgG as a negative control as described previously [63]. Immunoblot analysis Immunoblot analysis was performed as described previously [64] using anti-ACE2 (R&D Systems), anti-SARS-CoV-2 spike (Sino Biological) or anti-actin (Sigma) antibodies as primary antibodies. The intensity of the bands in Fig 5B was measured using ImageJ software. Statistics All statistical data were obtained by triplicates of three cell culture wells in an assay. All experiments were repeated at least two times in each assay and the representative data are shown in figures. Immunoblot analysis, indirect immunofluorescence analysis and lectin staining (Figs 2B, 5B–5D, 5F-a and S3) show one representative data, however, these experiments were repeated at least two times in each assay. Statistical significance was estimated using the two-tailed Student’s t test (*p < 0.05; **p < 0.01; N.S., not significant).

Supporting information S1 Fig. Chemical structures of sialylglyco-polyglutamic acid (PGA) and sialylglycopeptide (SGP). The structures are presented in the same formation as in Fig 1. For polymeric compounds, the estimated average molecular weights (Mw) are indicated, which have been obtained based on DS and averaged Mw of each polymer backbone. The values of m and n indicating degree of polymerization are rounded integers for average structures. Polymer compounds contain spacer groups, aminopentyl in α2-3SLN-PGA and α2-6SLN-PGA, and aminoethyl Lys in α2-6SLN-lipo-PGA, which are designed not to interfere with receptor-ligand interactions. A spacer in α2-6SLN-lipo-PGA is acylated, which has been shown to mimic sphingosine as in LS-PGA. https://doi.org/10.1371/journal.ppat.1010590.s001 (PDF) S2 Fig. The viability of cells and the effect of additional compounds on SARS-CoV-2 infection. (A) Schematic representation of the schedule for treating VeroE6/TMPRSS2 cells with compounds and SARS-CoV-2 in the infection assay. Black and white boxes indicate periods of treatment and nontreatment, respectively. (B, C) Viability of cells treated with or without the compounds was measured by quantification of survived cell numbers using ImageXpress Micro Confocal (Molecular Device). S1B and S1C Fig corresponds to Fig 2A and 2C, respectively. (D, E) SARS-CoV-2 infection assays were performed in the presence or absence of the indicated compounds. SARS-CoV-2 or SARS-CoV infection was determined by detecting SARS-CoV-2 RNA in the culture supernatant. Remdesivir, 10 μM; 2-O-methyl α-D-N-acetylneuraminic acid (Me-α-Neu5Ac), 60 mM; 2–6 sialyllactose sodium salt, 150 mM. https://doi.org/10.1371/journal.ppat.1010590.s002 (PDF) S3 Fig. The detection of sialic acid of the cells treated with or without neuraminidase. VeroE6/TMPRSS2 cells were treated with or without indicated neuraminidases for 2 h at 37°C, then cells were fixed and sialic acids were detected by lectin staining. Elderberry bark lectin for α2–6 linked sialic acid and Maackia amurensis lectin II for α2–3 linked sialic acid. Neuraminidase from Arthrobacter ureafaciens, 100 mU/ml; from Vibrio cholerae, 40 mU/ml; elderberry bark lectin, 20 μg/ml; Maackia amurensis lectin II, 20 μg/ml. https://doi.org/10.1371/journal.ppat.1010590.s003 (PDF)

[END]
---
[1] Url: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010590

Published and (C) by PLOS One
Content appears here under this condition or license: Creative Commons - Attribution BY 4.0.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/plosone/